Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-world evidence on the dosing and safety of C.E.R.A. in pediatric dialysis patients: findings from the International Pediatric Dialysis Network registries

L. Kohlhas, M. Studer, L. Rutten-Jacobs, SM. Reigner, A. Sander, HK. Yap, K. Vondrak, PA. Coccia, F. Cano, CP. Schmitt, BA. Warady, F. Schaefer, IPDN collaborators

. 2024 ; 39 (3) : 807-818. [pub] 20230811

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007011

BACKGROUND: This retrospective real-world study used data from two registries, International Pediatric Peritoneal Dialysis Network (IPPN) and International Pediatric Hemodialysis Network (IPHN), to characterize the efficacy and safety of continuous erythropoietin receptor activator (C.E.R.A.) in pediatric patients with chronic kidney disease (CKD) on peritoneal dialysis (PD) or hemodialysis (HD). METHODS: IPPN and IPHN collect prospective data (baseline and every 6 months) from pediatric PD and HD centers worldwide. Demographics, clinical characteristics, dialysis information, treatment, laboratory parameters, number and causes of hospitalization events, and deaths were extracted for patients on C.E.R.A. treatment (IPPN: 2007-2021; IPHN: 2013-2021). RESULTS: We analyzed 177 patients on PD (median age 10.6 years) and 52 patients on HD (median age 14.1 years) who had ≥ 1 observation while being treated with C.E.R.A. The median (interquartile range [IQR]) observation time under C.E.R.A. exposure was 6 (0-12.5) and 12 (0-18) months, respectively. Hemoglobin concentrations were stable over time; respective means (standard deviation) at last observation were 10.9 (1.7) g/dL and 10.4 (1.7) g/dL. Respective median (IQR) monthly C.E.R.A. doses at last observation were 3.5 (2.3-5.1) μg/kg, or 95 (62-145) μg/m2 and 2.1 (1.2-3.4) μg/kg, or 63 (40-98) μg/m2. Non-elective hospitalizations occurred in 102 (58%) PD and 32 (62%) HD patients. Seven deaths occurred (19.8 deaths per 1000 observation years). CONCLUSIONS: C.E.R.A. was associated with efficient maintenance of hemoglobin concentrations in pediatric patients with CKD on dialysis, and appeared to have a favorable safety profile. The current analysis revealed no safety signals.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007011
003      
CZ-PrNML
005      
20240423155645.0
007      
ta
008      
240412s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00467-023-05977-z $2 doi
035    __
$a (PubMed)37566114
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Kohlhas, Laura $u Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany
245    10
$a Real-world evidence on the dosing and safety of C.E.R.A. in pediatric dialysis patients: findings from the International Pediatric Dialysis Network registries / $c L. Kohlhas, M. Studer, L. Rutten-Jacobs, SM. Reigner, A. Sander, HK. Yap, K. Vondrak, PA. Coccia, F. Cano, CP. Schmitt, BA. Warady, F. Schaefer, IPDN collaborators
520    9_
$a BACKGROUND: This retrospective real-world study used data from two registries, International Pediatric Peritoneal Dialysis Network (IPPN) and International Pediatric Hemodialysis Network (IPHN), to characterize the efficacy and safety of continuous erythropoietin receptor activator (C.E.R.A.) in pediatric patients with chronic kidney disease (CKD) on peritoneal dialysis (PD) or hemodialysis (HD). METHODS: IPPN and IPHN collect prospective data (baseline and every 6 months) from pediatric PD and HD centers worldwide. Demographics, clinical characteristics, dialysis information, treatment, laboratory parameters, number and causes of hospitalization events, and deaths were extracted for patients on C.E.R.A. treatment (IPPN: 2007-2021; IPHN: 2013-2021). RESULTS: We analyzed 177 patients on PD (median age 10.6 years) and 52 patients on HD (median age 14.1 years) who had ≥ 1 observation while being treated with C.E.R.A. The median (interquartile range [IQR]) observation time under C.E.R.A. exposure was 6 (0-12.5) and 12 (0-18) months, respectively. Hemoglobin concentrations were stable over time; respective means (standard deviation) at last observation were 10.9 (1.7) g/dL and 10.4 (1.7) g/dL. Respective median (IQR) monthly C.E.R.A. doses at last observation were 3.5 (2.3-5.1) μg/kg, or 95 (62-145) μg/m2 and 2.1 (1.2-3.4) μg/kg, or 63 (40-98) μg/m2. Non-elective hospitalizations occurred in 102 (58%) PD and 32 (62%) HD patients. Seven deaths occurred (19.8 deaths per 1000 observation years). CONCLUSIONS: C.E.R.A. was associated with efficient maintenance of hemoglobin concentrations in pediatric patients with CKD on dialysis, and appeared to have a favorable safety profile. The current analysis revealed no safety signals.
650    _2
$a lidé $7 D006801
650    _2
$a dítě $7 D002648
650    _2
$a mladiství $7 D000293
650    _2
$a dialýza ledvin $x škodlivé účinky $7 D006435
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a prospektivní studie $7 D011446
650    _2
$a hemoglobiny $x analýza $7 D006454
650    _2
$a výsledek terapie $7 D016896
650    12
$a erythropoetin $7 D004921
650    12
$a chronická renální insuficience $x terapie $x farmakoterapie $7 D051436
650    _2
$a registrace $7 D012042
650    12
$a chronické selhání ledvin $x terapie $7 D007676
655    _2
$a časopisecké články $7 D016428
700    1_
$a Studer, Milena $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Rutten-Jacobs, Loes $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Reigner, Sylvie Meyer $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Sander, Anja $u Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany
700    1_
$a Yap, Hui-Kim $u Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore
700    1_
$a Vondrak, Karel $u Department of Pediatrics and Transplantation Center, University Hospital Motol, 2nd Medical Faculty Prague, Charles University Prague, Prague, Czech Republic
700    1_
$a Coccia, Paula A $u Division of Pediatric Nephrology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
700    1_
$a Cano, Francisco $u Division of Pediatric Nephrology, Hospital Dr. Luis Calvo Mackenna, Facultad de Medicina, Universidad de Chile, Santiago, Chile
700    1_
$a Schmitt, Claus Peter $u Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, Heidelberg, Germany
700    1_
$a Warady, Bradley A $u Division of Pediatric Nephrology, Children's Mercy Kansas City, Kansas City, MO, USA
700    1_
$a Schaefer, Franz $u Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, Heidelberg, Germany. Franz.Schaefer@med.uni-heidelberg.de $1 https://orcid.org/0000000175649937
710    2_
$a IPDN collaborators
773    0_
$w MED00003733 $t Pediatric nephrology $x 1432-198X $g Roč. 39, č. 3 (2024), s. 807-818
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37566114 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155641 $b ABA008
999    __
$a ok $b bmc $g 2081173 $s 1216778
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 39 $c 3 $d 807-818 $e 20230811 $i 1432-198X $m Pediatric nephrology $n Pediatr Nephrol $x MED00003733
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace